Claims for Patent: 8,227,509

Summary for Patent: 8,227,509

Title:	Methods of use of cyclopamine analogs
Abstract:	The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: ##STR00001##
Inventor(s):	Castro; Alfredo C. (Winchester, MA), Grogan; Michael J. (Winchester, MA), Matsui; William (Baltimore, MD), McGovern; Karen J. (Groton, MA), Tremblay; Martin R. (Melrose, MA)
Assignee:	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	13/191,545
Patent Claims:	1. A method for treating a cancer in a mammal, comprising administering to the mammal a compound selected from: ##STR00114## ##STR00115## ##STR00116## ##STR00117## ##STR00118## ##STR00119## ##STR00120## ##STR00121## ##STR00122## ##STR00123## or a pharmaceutically acceptable salt thereof, in combination with one or more other cancer treatments; wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a brain cancer, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a glioma, a breast cancer, a prostate cancer, a testicular cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, a neuroectodermal tumor, head and neck cancer, polycythemia Vera, Waldenstrom's macroglobulinemia, heavy chain disease, essential thrombocythemia, a sarcoma, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, a leiomyosarcoma, a cervical cancer, a uterine cancer, an endometrial cancer, a carcinoma, a bladder carcinoma, an epithelial carcinoma, a squamous cell carcinoma, an adenocarcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 2. The method of claim 1, wherein each of the one or more other cancer treatments is chosen from one or more of: one or more other chemotherapeutics; radiation therapy; a surgical treatment; one or more biotherapeutics; one or more anti-estrogens; one or more anti-androgens; endocrine therapy, or one or more LHRH agonists. 3. The method of claim 2, wherein at least one of the one or more other cancer treatments comprises administering one or more other chemotherapeutics. 4. The method of claim 3, wherein each of the one or more other chemotherapeutics is independently selected from gemcitabine, methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposides, prednisolone, dexamethasone, cytarbine, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, and vinorelbine. 5. The method of claim 3, wherein each of the one or more other chemotherapeutics is independently selected from a nitrogen mustard, a nitrosourea, an alkylsulphonate, a triazene, a platinum containing compound, a vinca alkaloid, a taxoid, an epipodophyllin, an anti-metabolite, a DHFR inhibitor, an IMP dehydrogenase Inhibitor, a ribonucleotide reductase inhibitor, a uracil analog, a cytosine analog, a purine analog, a Vitamin D3 analog, an isoprenylation inhibitor, a dopaminergic neurotoxin, a cell cycle inhibitor, an actinomycin, a bleomycin, an anthracycline, an MDR inhibitor, a Ca.sup.2+ ATPase inhibitor, imatinib, thalidomide, lenalidomide, erlotinib, gefitinib, sorafenib, sunitinib, and a proteasome inhibitor. 6. The method of claim 5, wherein each of the one or more other chemotherapeutics is independently selected from cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Estramustine, Melphalan, carmustine (BCNU), Lomustine (CCNU), busulfan, Treosulfan, Dacarbazine, Temozolomide, Cisplatin, Carboplatin, oxaliplatin, Vindesine, paclitaxel, Docetaxol, etoposide, Teniposide, Topotecan, 9-Aminocamptothecin, Camptoirinotecan, Crisnatol, Mytomycin C, methotrexate, Trimetrexate, mycophenolic acid, Tiazofurin, Ribavirin, EICAR, hydroxyurea, Deferoxamine, Fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, Capecitabine, cytarabine (ara C), Cytosine arabinoside, Fludarabine, mercaptopurine, Thioguanine, EB 1089, CB 1093, KH 1060, Lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, Actinomycin D, Dactinomycin, bleomycin A2, Bleomycin B2, Peplomycin, daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, Mitoxantrone, verapamil, and thapsigargin. 7. The method of claim 3, wherein each of the one or more other chemotherapeutics is independently selected from gemcitabine, Cisplatin, Epirubicin, and Fluorouracil. 8. The method of claim 3, wherein at least one of the one or more other chemotherapeutics is gemcitabine. 9. The method of claim 3, wherein at least one of the one or more chemotherapeutics is imatinib, thalidomide, lenalidomide, erlotinib, gefitinib, sorafenib, sunitinib, or bortezomib. 10. The method of claim 2, wherein at least one of the one or more other cancer treatments comprises administering one or more biotherapeutics. 11. The method of claim 10, wherein administering one or more biotherapeutics comprises administering one or more antibodies. 12. The method of claim 11, wherein at least one of the one or more antibodies is chosen from Avastin, Erbitux, Rituxan, or Bexxar. 13. The method of claim 2, wherein at least one of the one or more other cancer treatments comprises administering one or more anti-estrogens. 14. The method of claim 13, wherein at least one of the one or more anti-estrogens is chosen from Tamoxifen, Raloxifene, or Megestrol. 15. The method of claim 2, wherein at least one of the one or more other cancer treatments comprises radiation therapy or a surgical treatment. 16. The method of claim 1, wherein the method comprises administering the compound or pharmaceutically acceptable salt thereof in combination with a first other cancer treatment. 17. The method of claim 16, wherein the first other cancer treatment comprises administering one or more other chemotherapeutics. 18. The method of claim 17, wherein the first other cancer treatment comprises administering one chemotherapeutic. 19. The method of claim 18, wherein the chemotherapeutic is gemcitabine. 20. The method of claim 1, wherein the method comprises administering the compound or pharmaceutically acceptable salt thereof in combination with a first other cancer treatment and a second other cancer treatment. 21. The method of claim 20, wherein the first other cancer treatment comprises administering one or more other chemotherapeutics, and the second other cancer treatment comprises radiation therapy or a surgical treatment. 22. The method of claim 21, wherein at least one of the one or more other chemotherapeutics is gemcitabine. 23. The method of claim 1, wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a brain cancer, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a breast cancer, a prostate cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, head and neck cancer, polycythemia Vera, Waldenstrom's macroglobulinemia, heavy chain disease, essential thrombocythemia, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, a leiomyosarcoma, a bladder carcinoma, a squamous cell carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 24. The method of claim 1, wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a prostate cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, head and neck cancer, polycythemia Vera, essential thrombocythemia, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a leiomyosarcoma, a bladder carcinoma, a squamous cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 25. The method of claim 1, wherein the cancer is selected from of basal cell carcinoma, bile duct carcinoma, bladder carcinoma, breast cancer, chondrosarcoma, colon cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, glioma, hepatocellular cancer, lung cancer, medulloblastoma, melanoma, neuroectodermal tumors, osteogenic sarcoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, and testicular cancer. 26. The method of claim 1, wherein the cancer is selected from basal cell carcinoma, breast cancer, chondrosarcoma, colon cancer, esophageal cancer, gastric cancer, glioma, hepatocellular cancer, lung cancer, medulloblastoma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, and prostate cancer. 27. The method of claim 1, wherein the cancer is pancreatic cancer. 28. The method of claim 1, wherein the cancer is chondrosarcoma. 29. The method of claim 1, wherein the cancer is lung cancer. 30. The method of claim 29, wherein the lung cancer selected from small cell lung cancer and non-small cell lung cancer. 31. The method of claim 1, wherein the cancer is basal cell carcinoma. 32. The method of claim 1, wherein the cancer is medulloblastoma. 33. The method of claim 1, wherein the cancer is ovarian cancer. 34. The method according to claim 1, wherein the cancer is osteogenic sarcoma. 35. The method according to claim 1, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered concurrently. 36. The method according to claim 1, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered within the same treatment protocol. 37. The method according to claim 1, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered sequentially. 38. The method according to claim 1, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered with a time interval in between. 39. The method according to claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered first followed by administration of the other cancer treatment. 40. The method according to claim 1, wherein the other cancer treatment is administered first followed by administration of the compound or pharmaceutically acceptable salt thereof. 41. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered locally to a tumor. 42. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered systemically. 43. The method of claim 1, wherein the mode of administration of the compound or pharmaceutically acceptable salt thereof is inhalation, oral, intravenous, sublingual, ocular, transdermal, rectal, vaginal, topical, intramuscular, intraperitoneal, epidural, subcutaneous, buccal, or nasal. 44. The method of claim 43, wherein the mode of administration is oral, intravenous, or topical. 45. The method of claim 1, wherein the mammal is a human. 46. A method for treating cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of the formula: ##STR00124## or a pharmaceutically acceptable salt thereof in combination with one or more other cancer treatments; wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a brain cancer, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a glioma, a breast cancer, a prostate cancer, a testicular cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, a neuroectodermal tumor, head and neck cancer, polycythemia Vera, Waldenstrom's macroglobulinemia, heavy chain disease, essential thrombocythemia, a sarcoma, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, a leiomyosarcoma, a cervical cancer, a uterine cancer, an endometrial cancer, a carcinoma, a bladder carcinoma, an epithelial carcinoma, a squamous cell carcinoma, an adenocarcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 47. The method of claim 46, wherein each of the one or more other cancer treatments is chosen from one or more of: one or more other chemotherapeutics; radiation therapy; a surgical treatment; one or more biotherapeutics; one or more anti-estrogens; one or more anti-androgens; endocrine therapy, or one or more LHRH agonists. 48. The method of claim 47, wherein at least one of the one or more other cancer treatments comprises administering one or more other chemotherapeutics. 49. The method of claim 48, wherein each of the one or more other chemotherapeutics is independently selected from gemcitabine, methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposides, prednisolone, dexamethasone, cytarbine, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, and vinorelbine. 50. The method of claim 48, wherein each of the one or more other chemotherapeutics is independently selected from a nitrogen mustard, a nitrosourea, an alkylsulphonate, a triazene, a platinum containing compound, a vinca alkaloid, a taxoid, an epipodophyllin, an anti-metabolite, a DHFR inhibitor, an IMP dehydrogenase Inhibitor, a ribonucleotide reductase inhibitor, a uracil analog, a cytosine analog, a purine analog, a Vitamin D3 analog, an isoprenylation inhibitor, a dopaminergic neurotoxin, a cell cycle inhibitor, an actinomycin, a bleomycin, an anthracycline, an MDR inhibitor, a Ca.sup.2+ ATPase inhibitor, imatinib, thalidomide, lenalidomide, erlotinib, gefitinib, sorafenib, sunitinib, and a proteasome inhibitor. 51. The method of claim 50, wherein each of the one or more other chemotherapeutics is independently selected from cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Estramustine, Melphalan, carmustine (BCNU), Lomustine (CCNU), busulfan, Treosulfan, Dacarbazine, Temozolomide, Cisplatin, Carboplatin, oxaliplatin, Vindesine, paclitaxel, Docetaxol, etoposide, Teniposide, Topotecan, 9-Aminocamptothecin, Camptoirinotecan, Crisnatol, Mytomycin C, methotrexate, Trimetrexate, mycophenolic acid, Tiazofurin, Ribavirin, EICAR, hydroxyurea, Deferoxamine, Fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, Capecitabine, cytarabine (ara C), Cytosine arabinoside, Fludarabine, mercaptopurine, Thioguanine, EB 1089, CB 1093, KH 1060, Lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, Actinomycin D, Dactinomycin, bleomycin A2, Bleomycin B2, Peplomycin, daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, Mitoxantrone, verapamil, and thapsigargin. 52. The method of claim 48, wherein each of the one or more other chemotherapeutics is independently selected from gemcitabine, Cisplatin, Epirubicin, and Fluorouracil. 53. The method of claim 48, wherein at least one of the one or more other chemotherapeutics is gemcitabine. 54. The method of claim 48, wherein at least one of the one or more chemotherapeutics is imatinib, thalidomide, lenalidomide, erlotinib, gefitinib, sorafenib, sunitinib, or bortezomib. 55. The method of claim 47, wherein at least one of the one or more other cancer treatments comprises administering one or more biotherapeutics. 56. The method of claim 55, wherein administering one or more biotherapeutics comprises administering one or more antibodies. 57. The method of claim 56, wherein at least one of the one or more antibodies is chosen from Avastin, Erbitux, Rituxan, or Bexxar. 58. The method of claim 47, wherein at least one of the one or more other cancer treatments comprises administering one or more anti-estrogens. 59. The method of claim 58, wherein at least one of the one or more anti-estrogens is chosen from Tamoxifen, Raloxifene, or Megestrol. 60. The method of claim 47, wherein at least one of the one or more other cancer treatments comprises radiation therapy or a surgical treatment. 61. The method of claim 46, wherein the method comprises administering the compound or pharmaceutically acceptable salt thereof in combination with a first other cancer treatment. 62. The method of claim 61, wherein the first other cancer treatment comprises administering one or more other chemotherapeutics. 63. The method of claim 62, wherein the first other cancer treatment comprises administering one chemotherapeutic. 64. The method of claim 63, wherein the chemotherapeutic is gemcitabine. 65. The method of claim 46, wherein the method comprises administering the compound or pharmaceutically acceptable salt thereof in combination with a first other cancer treatment and a second other cancer treatment. 66. The method of claim 65, wherein the first other cancer treatment comprises administering one or more other chemotherapeutics, and the second other cancer treatment comprises radiation therapy or a surgical treatment. 67. The method of claim 66, wherein at least one of the one or more other chemotherapeutics is gemcitabine. 68. The method of claim 46, wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a brain cancer, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a breast cancer, a prostate cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, head and neck cancer, polycythemia Vera, Waldenstrom's macroglobulinemia, heavy chain disease, essential thrombocythemia, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, a leiomyosarcoma, a bladder carcinoma, a squamous cell carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 69. The method of claim 46, wherein the cancer is chosen from one or more of: a cancer of the pulmonary system, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, a pancreatic cancer, a lung cancer, a medullobastoma, a basal cell carcinoma, a prostate cancer, an esophageal cancer, a hepatocellular cancer, a gastric cancer, a gastrointestinal stromal tumor (GIST), a colon cancer, a colorectal cancer, an ovarian cancer, a melanoma, head and neck cancer, polycythemia Vera, essential thrombocythemia, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a leiomyosarcoma, a bladder carcinoma, a squamous cell carcinoma, a hepatoma, a bile duct carcinoma, a neuroendocrine cancer, or a carcinoid tumor. 70. The method of claim 46, wherein the cancer is selected from basal cell carcinoma, bile duct carcinoma, bladder carcinoma, breast cancer, chondrosarcoma, colon cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, glioma, hepatocellular cancer, lung cancer, medulloblastoma, melanoma, neuroectodermal tumors, osteogenic sarcoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, and testicular cancer. 71. The method of claim 46, wherein the cancer is selected from basal cell carcinoma, breast cancer, chondrosarcoma, colon cancer, esophageal cancer, gastric cancer, glioma, hepatocellular cancer, lung cancer, medulloblastoma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, and prostate cancer. 72. The method of claim 46, wherein the cancer is pancreatic cancer. 73. The method of claim 46, wherein the cancer is chondrosarcoma. 74. The method of claim 46, wherein the cancer is lung cancer. 75. The method of claim 74, wherein the lung cancer selected from small cell lung cancer and non-small cell lung cancer. 76. The method of claim 46, wherein the cancer is basal cell carcinoma. 77. The method of claim 46, wherein the cancer is medulloblastoma. 78. The method of claim 46, wherein the cancer is ovarian cancer. 79. The method according to claim 46, wherein the cancer is osteogenic sarcoma. 80. The method according to claim 46, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered concurrently. 81. The method according to claim 46, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered within the same treatment protocol. 82. The method according to claim 46, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered sequentially. 83. The method according to claim 46, wherein the compound or pharmaceutically acceptable salt thereof and the one or more other cancer treatments are administered with a time interval in between. 84. The method according to claim 46, wherein the compound or pharmaceutically acceptable salt thereof is administered first followed by administration of the other cancer treatment. 85. The method according to claim 46, wherein the other cancer treatment is administered first followed by administration of the compound or pharmaceutically acceptable salt thereof. 86. The method of claim 46, wherein the compound or pharmaceutically acceptable salt thereof is administered locally to a tumor. 87. The method of claim 46, wherein the compound or pharmaceutically acceptable salt thereof is administered systemically. 88. The method of claim 46, wherein the mode of administration of the compound or pharmaceutically acceptable salt thereof is inhalation, oral, intravenous, sublingual, ocular, transdermal, rectal, vaginal, topical, intramuscular, intraperitoneal, epidural, subcutaneous, buccal, or nasal. 89. The method of claim 88, wherein the mode of administration is oral, intravenous, or topical. 90. The method of claim 46, wherein the mammal is a human. 91. A method for treating pancreatic cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of the formula: ##STR00125## or a pharmaceutically acceptable salt thereof in combination with gemcitabine. 92. The method of claim 91, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

Details for Patent 8,227,509

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-12-28
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-12-28
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-12-28